Jefferies is out with its report today on Valeant Pharmaceuticals VRX, maintaining Buy.
In a note to clients, Jefferies writes, "VRX has been the top performing Spec Pharma stock in 2011 (~40% YTD), but with a high degree of confidence in management's ability to execute on its growth objectives, and a view that Street estimates are too low, we see plenty of upside room to our $53 PT."
At the time of posting, shares of VRX were trading at $39.57, down 1.12% from Tuesday's close.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Posted In: Analyst ColorPrice TargetAnalyst RatingsHealth CareJefferiesPharmaceuticalsvaleant pharmaceuticals
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in